Cell Therapy Development for Breast Cancer

Cell Therapy Development for Breast Cancer

Cell therapy is an innovative approach in the treatment of breast cancer, utilizing living cells to target and eradicate cancerous cells. This strategy encompasses various modalities, including immune cell therapies, stem cell therapies, and genetically modified cell therapies. The primary objective is to harness the body's own immune system or utilize engineered cells to recognize and destroy tumor cells more effectively than conventional treatments. Alfa Cytology provides a comprehensive suite of services dedicated to the development of cell therapies for breast cancer.

Introduction to Cellular Immunotherapies

Breast cancer (BC) is one of the malignant tumors that seriously threaten women's life and health. Traditional treatment methods have the disadvantages of "easy transfer and side effects". Cellular immunotherapy is an emerging BC treatment method. By activating or restoring the tumor-killing function of the human immune system, it can effectively avoid cancer recurrence and metastasis, and further improve the survival rate of BC patients. At present, the main therapies include cytokine-induced killer cell therapy, dendritic cell therapy, CAR-T therapy, CAR-NK therapy, ACTL tumor cell-targeted therapy, CLS therapy, DC-T cell therapy, etc.

From MSCs to CAR-MSCs in cellular immunotherapy.Fig.1 From MSCs to CAR-MSCs in cellular immunotherapy. (Yan L, et al., 2023)

Our Services

Alfa Cytology can provide you with BC cellular immunotherapy development services. Cellular immunotherapy can help the immune system identify and attack specific cancer cells, strengthen immune cells, destroy cancer, and provide the body with additional substances to enhance the body's immune response. Our services include:

Advantages of Cellular Immunotherapy

  • High security
  • Targeted
  • Comprehensiveness
  • Wide range of indications

Alfa Cytology' team is composed of highly educated and highly qualified professionals with good professional backgrounds and BC research experience. If you are interested in learning more about our BC cell immunotherapy development services, please feel free to contact us. Our professional and patient staff will contact you as soon as possible.

Reference

  1. Yan L, et al. The role of MSCs and CAR-MSCs in cellular immunotherapy. Cell Commun Signal. 2023 Aug 1;21(1):187.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.